{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:18:20Z","timestamp":1789075100345,"version":"build-2803163510"},"reference-count":34,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Spinal muscular atrophy (SMA) treatment has evolved with the approval of nusinersen, onasemnogene abeparvovec, and risdiplam. This study aims to assess the post-marketing safety profile of these therapies through the spontaneous adverse drug reaction (ADR) reports available in EudraVigilance (EV). Methods: Data from EV were retrieved via adrreports.eu for the suspected ADRs associated with nusinersen, onasemnogene abeparvovec, and risdiplam from their approval in the European Economic Area (EEA) to 31 December 2024. The ADR reports were exported and analysed using descriptive statistics in Microsoft Excel. Reporting odds ratios (RORs) with 95% confidence intervals (CIs) were calculated for suspected ADRs, focusing on reactions with a lower limit of the 95% CI exceeding 1. Results: A total of 3196, 806, and 956 individual case safety reports (ICSRs) were identified for nusinersen, onasemnogene abeparvovec, and risdiplam, respectively. The most frequently reported ADRs with significantly increased RORs included post-lumbar puncture syndrome (nusinersen: 11%), pyrexia (onasemnogene abeparvovec: 23%), and pneumonia (risdiplam: 9%). While some ADRs were therapy-specific, others were consistent with SMA disease progression and complications. Onasemnogene abeparvovec showed a notable prevalence of hepatotoxicity, while risdiplam was associated with gastrointestinal and respiratory events. Conclusions: To conclude, the analysis reinforces the known safety profiles of these SMA treatments while highlighting potential areas for further investigation. ADRs related to SMA complications require careful differentiation from true drug-related effects. Future pharmacovigilance efforts should focus on long-term safety assessments and real-world evidence to optimize treatment strategies.<\/jats:p>","DOI":"10.3390\/jcm14093173","type":"journal-article","created":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T20:10:27Z","timestamp":1746389427000},"page":"3173","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Post-Marketing Safety of Spinal Muscular Atrophy Therapies: Analysis of Spontaneous Adverse Drug Reactions from EudraVigilance"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7848-6600","authenticated-orcid":false,"given":"Andrej","family":"Belan\u010di\u0107","sequence":"first","affiliation":[{"name":"Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Mas","sequence":"additional","affiliation":[{"name":"Agency for Medicinal Products and Medical Devices, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Mileti\u0107","sequence":"additional","affiliation":[{"name":"Agency for Medicinal Products and Medical Devices, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2933-5726","authenticated-orcid":false,"given":"Barbara","family":"Kova\u010di\u0107 Bytyqi","sequence":"additional","affiliation":[{"name":"Agency for Medicinal Products and Medical Devices, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6295-6580","authenticated-orcid":false,"given":"Dinko","family":"Vitezi\u0107","sequence":"additional","affiliation":[{"name":"Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","article-title":"Spinal muscular atrophies","volume":"62","author":"Darras","year":"2015","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014A literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Chen, T.H. (2020). New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093297"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/gt.2017.52","article-title":"The clinical landscape for SMA in a new therapeutic era","volume":"24","author":"Talbot","year":"2017","journal-title":"Gene Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.nmd.2017.05.011","article-title":"Spinal muscular atrophy: A changing phenotype beyond the clinical trials","volume":"27","author":"Tizzano","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40271-020-00415-w","article-title":"\u201cThe Whole Game is Changing and You\u2019ve Got Hope\u201d: Australian Perspectives on Treatment Decision Making in Spinal Muscular Atrophy","volume":"13","author":"Farrar","year":"2020","journal-title":"Patient"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","unstructured":"(2025, March 25). European Public Assessment Report (EPAR) for Spinraza [Internet]. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spinraza."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): An open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): An open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_13","unstructured":"(2025, March 25). European Public Assessment Report (EPAR) for Zolgensma [Internet]. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls","volume":"385","author":"Darras","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): A phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_16","unstructured":"(2025, March 25). European Public Assessment Report (EPAR) for Evrysdi [Internet]. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evrysdi."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/bcp.16140","article-title":"Past, present and future of drug safety: Editorial","volume":"90","author":"Rieder","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_18","unstructured":"(2025, March 25). EudraVigilance [Internet]. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eudravigilance."},{"key":"ref_19","unstructured":"(2025, March 25). Suspected Adverse Drug Reactions\u2014Background [Internet]. Available online: https:\/\/www.adrreports.eu\/en\/background.html."},{"key":"ref_20","unstructured":"(2025, March 25). Suspected Adverse Drug Reactions\u2014Data Source [Internet]. Available online: https:\/\/www.adrreports.eu\/en\/data_source.html."},{"key":"ref_21","unstructured":"(2025, March 25). Suspected Adverse Drug Reactions\u2014Understanding a Web Report [Internet]. Available online: https:\/\/www.adrreports.eu\/en\/understanding_reports.html."},{"key":"ref_22","unstructured":"(2025, March 25). EudraVigilance System Overview [Internet]. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eudravigilance\/eudravigilance-system-overview."},{"key":"ref_23","unstructured":"(2025, March 25). European Medicines Agency Policy on Access to EudraVigilance Data for Medicinal Products for Human Use [Internet]. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/other\/european-medicines-agency-policy-access-eudravigilance-data-medicinal-products-human-use-revision-4_en.pdf."},{"key":"ref_24","unstructured":"(2025, March 25). MedDRA Introductory Guide [Internet]. Available online: https:\/\/admin.new.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_27_1_English.pdf."},{"key":"ref_25","unstructured":"(2025, March 25). Access to EudraVigilance data [Internet]. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eudravigilance\/access-eudravigilance-data."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1007\/s12325-024-02845-6","article-title":"Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy","volume":"41","author":"Kokaliaris","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Belan\u010di\u0107, A., Strbad, T., Ku\u010dan \u0160tigli\u0107, M., and Vitezi\u0107, D. (2024). Switching from Nusinersen to Risdiplam: A Croatian Real-World Experience on Effectiveness and Safety. J. Pers. Med., 14.","DOI":"10.20944\/preprints202311.1564.v1"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00228-008-0494-6","article-title":"Women encounter ADRs more often than do men","volume":"64","author":"Zopf","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J. Child Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.nmd.2015.09.009","article-title":"1st Italian SMA Family Association Consensus Meeting: Management and recommendations for respiratory involvement in spinal muscular atrophy (SMA) types I-III, Rome, Italy, 30\u201331 January 2015","volume":"25","author":"Sansone","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"ref_31","first-page":"113","article-title":"Proximal spinal muscular atrophy: Current orthopedic perspective","volume":"6","author":"Haaker","year":"2013","journal-title":"Appl. Clin. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1177\/0883073813503988","article-title":"Nutritional practices at a glance: Spinal muscular atrophy type I nutrition survey findings","volume":"29","author":"Davis","year":"2014","journal-title":"J. Child. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.nmd.2012.04.008","article-title":"Observational study of caloric and nutrient intake, bone density, and body composition in infants and children with spinal muscular atrophy type I","volume":"22","author":"Poruk","year":"2012","journal-title":"Neuromuscul. Disord."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Yu, L., and Liu, L. (2024). Exploration of adverse events associated with risdiplam use: Retrospective cases from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0298609"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/9\/3173\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:26:50Z","timestamp":1760030810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/9\/3173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["jcm14093173"],"URL":"https:\/\/doi.org\/10.3390\/jcm14093173","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,3]]}}}